GET DAILY SIGNALSHealth Care Select Sector SPDR Fund (XLV) Rises +11% Over 30 Days on Defensive Rotation
Key Takeaways
- XLV climbed roughly 11% over the trailing 30 days, extending a broader advance as investors rotated into defensive, large-cap healthcare names.
- Top holding Eli Lilly traded near record highs on GLP-1 leadership and a pipeline of new weight-loss candidates entering regulatory review.
- A rotation away from technology and AI-related equities, combined with solid UnitedHealth Group results, reinforced the healthcare bid.
- The fund holds roughly 60 market-cap-weighted healthcare stocks with a 0.08% expense ratio, with pharmaceuticals and managed care dominating exposure.
- Over the last quarter, XLV advanced about 14%, consistent with a trend-driven rally rather than sharp volatility.
- For additional detail, explore XLV Price Targets and Forecast pages for deeper technical and predictive analysis.
- Discover new trading ideas with Trending AI Robots to complement your research workflow.
XLV ETF Overview and Holdings Breakdown
XLV is a passively managed exchange-traded fund that seeks to track the Health Care Select Sector Index, which comprises healthcare companies drawn from the S&P 500. The fund employs a replication strategy, typically investing at least 95% of its assets in the index's constituents. With roughly 60 holdings and an expense ratio of 0.08%, XLV is among the lowest-cost vehicles for broad U.S. healthcare equity exposure, managing tens of billions of dollars in assets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Portfolio exposure is heavily concentrated in large-cap pharmaceuticals, biotechnology, healthcare equipment, and managed-care providers. The largest holdings include Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), UnitedHealth Group (UNH), and Merck (MRK). This top-heavy structure means a small number of mega-cap pharmaceutical and managed-care names disproportionately drive the fund's returns, which helps explain its recent strength.
Recent Price Performance: 30 Days and Quarterly Trends
Over the trailing 30 days, XLV advanced approximately 11%, measured from an adjusted closing level near $166 to the latest close around $184.60. The move was largely trend-driven and steady, punctuated by a record high in mid-October, rather than a sharp, single-session spike. From what I see, this reflects steady institutional interest rather than speculative fervor.
The broader quarterly trend has been even more constructive. From a closing level near $162 roughly three months earlier, XLV gained about 14%, reflecting a sustained rotation into healthcare leadership rather than a short-lived bounce. This contrasts with the more volatile, range-bound behavior seen earlier in the year and underscores improving investor conviction in the sector.
Key Drivers Behind the 30-Day Advance
The primary catalyst was a market-wide rotation out of technology and AI-related equities and into defensive, cash-flow-generative sectors. As concerns around AI-related spending intensified, investors sought relative stability in large-cap healthcare, lifting XLV to record territory. One thing that stands out is how this shift rewarded the fund's concentrated exposure to established names.
The fund's largest holding, Eli Lilly (LLY), traded near all-time highs, supported by its leadership in GLP-1 obesity and diabetes treatments and additional weight-loss candidates moving toward regulatory review. UnitedHealth Group (UNH) also contributed after reporting solid quarterly results that reassured investors about managed-care fundamentals. Broad-based participation across Johnson & Johnson (JNJ) and AbbVie (ABBV) further reinforced the advance, as steady institutional flows into the fund accompanied the move.
Factors Supporting the Quarterly Performance
The three-month trend reflects a longer-term sector rotation into healthcare. A key structural shift came from voluntary drug-pricing agreements reached by large-cap drugmakers, which removed a major policy overhang that had weighed on valuations. Combined with the GLP-1 obesity theme and defensive positioning amid broader equity-market volatility, healthcare emerged as a leading S&P 500 sector.
Major holdings benefited from resilient earnings and steady demand, while the fund's low-cost, diversified structure attracted sustained institutional interest. Unlike a momentum-driven move concentrated in one or two names, the quarterly advance was relatively broad-based across pharmaceuticals, biotechnology, and healthcare equipment, supporting a more durable uptrend.
Looking Ahead: Factors to Monitor
Looking ahead, the most important factors for XLV are the durability of the defensive rotation, the trajectory of the GLP-1 and obesity drug market, and the earnings cycle of its largest pharmaceutical and managed-care holdings. Interest-rate expectations and inflation trends will remain relevant, as they influence the relative appeal of defensive, dividend-oriented equities versus growth stocks.
Investors should also monitor policy and regulatory developments, including any revival of drug-pricing proposals, as well as capital flows into and out of healthcare ETFs. Patent cliffs and pipeline execution at major constituents, along with the pace of a potential recovery in technology equities that could draw capital back out of healthcare, represent the principal risks to continued leadership. The fund's concentrated top holdings mean that developments at a handful of mega-cap names can disproportionately shape performance. I’m watching this closely as the sector dynamics evolve.
Enhancing Research with Tickeron Tools
In my view, Tickeron’s AI Screener has become a useful part of my workflow for spotting sector rotations like the one playing out in healthcare. It lets me apply technical, fundamental, and pattern-based filters across thousands of securities to surface candidates more efficiently than manual review alone. This has helped me cross-check ideas around XLV holdings without getting lost in raw data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Momentum Indicator for XLV turns positive, indicating new upward trend
XLV saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 83 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 221 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XLV broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement